Copyright © Genix Pharma Private Limited, all rights are reserved.
Brand Name: Pire
Active: Rifampicin + Isoniazid + Pyrazinamide + Ethambutol HCl
Therapeutical Class: Anti-Tuberclosis
Indication: Pire 2 is indicated in the comtinuation phase of the short-course treatment for minimum 4-months for new cases of pulmonary tuberculosis. Pire 3 is indicated in the initial phase of the short-course treatment for 5 months of retreatment cases of pulmonary tuberculosis. Pire 4+ is indicated in the initial phase of the short-course treatment for 2-3 months of pulmonary tuberculosis.
Latest Launched Product
